SCHEMBL7231990

SCHEMBL7231990

O=C(O)c1ccccc1Nc1cccc(-c2ccc3ccccc3c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 2/20 0.64
FABP4 P15090 6/20 0.63
FABP3 P05413 3/20 0.63
FABP5 Q01469 3/20 0.63
SIRT2 Q8IXJ6 2/20 0.62
SIRT1 Q96EB6 2/20 0.62
TAS2R14 Q9NYV8 2/20 0.56
PTGS1 P23219 1/20 0.56
PTGS2 P35354 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
CTSV O60911 1/20 0.54
CTSL P07711 1/20 0.54
MAPT P10636 2/20 0.54
KDM4E B2RXH2 2/20 0.54
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15673372 0.88 SIRT2 (0.77) FTOFABP4FABP3FABP5SIRT2
SCHEMBL7238038 0.85 MAPT (0.61) FTOFABP4FABP3FABP5SIRT2
SCHEMBL10144151 0.85 FABP4 (0.62) FTOFABP4FABP3FABP5TAS2R14
Fenamic Acid SCHEMBL7265127 0.82 FABP4 (0.77) FTOFABP4FABP3FABP5TAS2R14
SCHEMBL4223666 0.81 SIRT2 (0.61) FABP4SIRT2SIRT1TAS2R14PTGS1
SCHEMBL7229231 0.81 DHODH (0.64) SIRT2PTGS1PTGS2MAPTMEN1
SCHEMBL28672317 0.80 SIRT2 (0.61) FABP4SIRT2SIRT1TAS2R14PTGS1
SCHEMBL25568703 0.80 ALDH1A1 (0.47) FTOFABP4FABP3FABP5SIRT2
SCHEMBL23868895 0.78 ALDH1A1 (0.68) SIRT2PTGS1PTGS2MAPTKDM4E
SCHEMBL18271491 0.78 ALDH1A1 (0.62) SIRT2SIRT1MAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-20 US disclosed
WO-2003006443-A2 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production TERT, POT1, REV1 FTO 2546/4885FABP4 4393/4885FABP3 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.